 AIM ImmunoTech Inc has progressed a step further in its bid to get Ampligen into a clinical trial to test it as an infusion therapy for Post-COVID-19 Cognitive Dysfunction PCCD - a new and serious coronavirus-induced disease for which there is currently no treatment. The FDA has deemed a meeting request sufficient for transfer now to the regulators Division of Neurology by the FDAs Covid scientific technical triage team. 